Tefibazumab
From Wikipedia, the free encyclopedia
|
Tefibazumab?
|
|
| Therapeutic monoclonal antibody | |
| Source | Humanized |
| Target | ? |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C6548H10122N1730O2034S44 |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Tefibazumab (marketed under the brand name Aurexis) is a humanized monoclonal antibody used to treat bacterial infections.
It was developed by Inhibitex.[1]
[edit] See also
[edit] References
- ^ John JF (2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Curr. Opin. Mol. Ther. 8 (5): 455–60. PMID 17078388.
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||||
